Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 173970, 7 pages
http://dx.doi.org/10.1155/2015/173970
Research Article

Serum Caveolin-1 as a Novel Biomarker in Idiopathic Pulmonary Artery Hypertension

1Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan
2School of Medicine, Chung Shan Medical University, Taichung, Taiwan
3School of Medicine, China Medical University, Taichung, Taiwan
4Department of Education and Research, Taichung Veterans General Hospital, Taichung, Taiwan
5Department of Life Science, Tunghai University, Taichung, Taiwan
6Institute of Clinical Medicine, Cardiovascular Research Center, Taiwan
7Department of Medicine, National Yang Ming University School of Medicine, Taipei, Taiwan
8Department of Biomedical Engineering & Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan

Received 22 June 2015; Revised 16 August 2015; Accepted 18 August 2015

Academic Editor: Renzhi Han

Copyright © 2015 Kuo-Yang Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Peacock, “Treatment of pulmonary hypertension,” British Medical Journal, vol. 326, no. 7394, pp. 835–836, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. G. E. D'Alonzo, R. J. Barst, S. M. Ayres et al., “Survival in patients with primary pulmonary hypertension: results from a national prospective registry,” Annals of Internal Medicine, vol. 115, no. 5, pp. 343–349, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. D. B. Badesch, G. E. Raskob, C. G. Elliott et al., “Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry,” Chest, vol. 137, no. 2, pp. 376–387, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Galiè, M. M. Hoeper, M. Humbert et al., “Guidelines for the diagnosis and treatment of pulmonary hypertension,” European Heart Journal, vol. 30, pp. 2493–2537, 2009. View at Google Scholar
  5. V. V. McLaughlin, S. L. Archer, D. B. Badesch et al., “ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association,” Circulation, vol. 119, pp. 2250–2294, 2009. View at Google Scholar
  6. M. D. McGoon, R. L. Benza, P. Escribano-Subias et al., “Pulmonary arterial hypertension: epidemiology and registries,” Journal of the American College of Cardiology, vol. 62, no. 25, supplement, pp. D51–D59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Habib and A. Torbicki, “The role of echocardiography in the diagnosis and management of patients with pulmonary hypertension,” European Respiratory Review, vol. 19, no. 118, pp. 288–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. D. B. Badesch, H. C. Champion, M. A. Gomez Sanchez et al., “Diagnosis and assessment of pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 54, no. 1, pp. S55–S66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Nagaya, T. Nishikimi, M. Uematsu et al., “Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension,” Circulation, vol. 102, no. 8, pp. 865–870, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Nagaya, M. Uematsu, T. Satoh et al., “Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 2, pp. 487–492, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. J.-L. Cracowski and H. H. Leuchte, “The potential of biomarkers in pulmonary arterial hypertension,” The American Journal of Cardiology, vol. 110, no. 6, pp. S32–S38, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Rafeq, A. M. Shah, and I. R. Preston, “Biomarkers in pulmonary arterial hypertension,” International Journal of Clinical Practice, vol. 63, no. 162, pp. 36–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Humbert, N. W. Morrell, S. L. Archer et al., “Cellular and molecular pathobiology of pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 43, no. 12, supplement, pp. 13S–24S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Sakao, K. Tatsumi, and N. F. Voelkel, “Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation,” Respiratory Research, vol. 10, article 95, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. R. Wilkins, “Pulmonary hypertension: the science behind the disease spectrum,” European Respiratory Review, vol. 21, no. 123, pp. 19–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Drab, P. Verkade, M. Elger et al., “Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice,” Science, vol. 293, no. 5539, pp. 2449–2452, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. L. A. Carver and J. E. Schnitzer, “Caveolae: mining little caves for new cancer targets,” Nature Reviews Cancer, vol. 3, no. 8, pp. 571–581, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. Y.-Y. Zhao, Y. Liu, R.-V. Stan et al., “Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 17, pp. 11375–11380, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-F. Jasmin, I. Mercier, J. Dupuis, H. B. Tanowitz, and M. P. Lisanti, “Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy,” Circulation, vol. 114, no. 9, pp. 912–920, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. R. O. D. Achcar, Y. Demura, P. R. Rai et al., “Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension,” Chest, vol. 129, no. 3, pp. 696–705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-Y. Zhao, Y. D. Zhao, M. K. Mirza et al., “Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration,” Journal of Clinical Investigation, vol. 119, no. 7, pp. 2009–2018, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Liu, W.-P. Li, T. Machleidt, and R. G. W. Anderson, “Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells,” Nature Cell Biology, vol. 1, no. 6, pp. 369–375, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. S. A. Tahir, S. Kurosaka, R. Tanimoto, A. A. Goltsov, S. Park, and T. C. Thompson, “Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models,” Cancer Biology and Therapy, vol. 14, no. 2, pp. 117–126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S. A. Tahir, C. Ren, T. L. Timme et al., “Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer,” Clinical Cancer Research, vol. 9, part 1, no. 10, pp. 3653–3659, 2003. View at Google Scholar · View at Scopus
  25. H. H. Patel, S. Zhang, F. Murray et al., “Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension,” The FASEB Journal, vol. 21, no. 11, pp. 2970–2979, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Mathew, “Cell-specific dual role of caveolin-1 in pulmonary hypertension,” Pulmonary Medicine, vol. 2011, Article ID 573432, 12 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. L. C. Huber, A. Soltermann, M. Fischler et al., “Caveolin-1 expression and hemodynamics in COPD patients,” Open Respiratory Medicine Journal, vol. 3, pp. 73–78, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. J. L. Januzzi Jr., S. U. Rehman, A. A. Mohammed et al., “Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction,” Journal of the American College of Cardiology, vol. 58, no. 18, pp. 1881–1889, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Nagaya, T. Nishikimi, Y. Okano et al., “Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension,” Journal of the American College of Cardiology, vol. 31, no. 1, pp. 202–208, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Y. Chi, E. Y. Kim, H. J. Ban et al., “Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease,” Lung, vol. 190, no. 3, pp. 271–276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. J. W. Wertz and P. M. Bauer, “Caveolin-1 regulates BMPRII localization and signaling in vascular smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 375, no. 4, pp. 557–561, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Ramos, M. W. Lamé, H. J. Segall, and D. W. Wilson, “The BMP type II receptor is located in lipid rafts, including caveolae, of pulmonary endothelium in vivo and in vitro,” Vascular Pharmacology, vol. 44, no. 1, pp. 50–59, 2006. View at Publisher · View at Google Scholar · View at Scopus